Exploring potential anti-inflammatory effects of medicinal cannabis.

Gurgenci, T; Kijanka, G; Greer, R; Huggett, G; Good, P; Moniruzzaman, M; Hardy, J

Exploring potential anti-inflammatory effects of medicinal cannabis.

Gurgenci, T Kijanka, G Greer, R Huggett, G Good, P

Moniruzzaman, M Hardy, J

Permalink

Publisher:: SPRINGER
Publication Type:: Journal Article
Citation:: Support Care Cancer, 2023, 31, (12), pp. 629
Issue Date:: 2023-10-14

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Download Published versionAdobe PDF (595.27 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Gurgenci, T
dc.contributor.author	Kijanka, G
dc.contributor.author	Greer, R
dc.contributor.author	Huggett, G
dc.contributor.author	Good, P https://orcid.org/0000-0002-8198-0375
dc.contributor.author	Moniruzzaman, M
dc.contributor.author	Hardy, J
dc.date.accessioned	2024-07-10T00:18:49Z
dc.date.available	2023-09-22
dc.date.available	2024-07-10T00:18:49Z
dc.date.issued	2023-10-14
dc.identifier.citation	Support Care Cancer, 2023, 31, (12), pp. 629
dc.identifier.issn	0941-4355
dc.identifier.issn	1433-7339
dc.identifier.uri	http://hdl.handle.net/10453/179759
dc.description.abstract	PURPOSE: Inflammation is thought to play a key role in malignant disease and may play a significant part in the expression of cancer-related symptoms. Cannabidiol (CBD) is a bioactive compound in cannabis and is reported to have significant anti-inflammatory properties. METHOD: Serial C-reactive protein (CRP) levels were measured in all participants recruited to a randomised controlled trial of CBD versus placebo in patients with symptoms related to advanced cancer. A panel of inflammatory cytokines was measured over time in a subset of these patients. RESULTS: There was no difference between the two arms in the trajectory of CRP or cytokine levels from baseline to day 28. CONCLUSION: We were unable to demonstrate an anti-inflammatory effect of CBD in cancer patients. TRIAL REGISTRATION: ANZCTR 26180001220257, registered 20/07/2018.
dc.format	Electronic
dc.language	eng
dc.publisher	SPRINGER
dc.relation.ispartof	Support Care Cancer
dc.relation.isbasedon	10.1007/s00520-023-08069-8
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.classification	32 Biomedical and clinical sciences
dc.subject.classification	42 Health sciences
dc.subject.classification	52 Psychology
dc.subject.mesh	Humans
dc.subject.mesh	Medical Marijuana
dc.subject.mesh	Cannabidiol
dc.subject.mesh	Cannabis
dc.subject.mesh	Anti-Inflammatory Agents
dc.subject.mesh	Neoplasms
dc.subject.mesh	Humans
dc.subject.mesh	Cannabis
dc.subject.mesh	Neoplasms
dc.subject.mesh	Cannabidiol
dc.subject.mesh	Anti-Inflammatory Agents
dc.subject.mesh	Medical Marijuana
dc.subject.mesh	Humans
dc.subject.mesh	Medical Marijuana
dc.subject.mesh	Cannabidiol
dc.subject.mesh	Cannabis
dc.subject.mesh	Anti-Inflammatory Agents
dc.subject.mesh	Neoplasms
dc.title	Exploring potential anti-inflammatory effects of medicinal cannabis.
dc.type	Journal Article
utslib.citation.volume	31
utslib.location.activity	Germany
utslib.for	11 Medical and Health Sciences
utslib.for	17 Psychology and Cognitive Sciences
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
dc.date.updated	2024-07-10T00:18:40Z
pubs.issue	12
pubs.publication-status	Published online
pubs.volume	31
utslib.citation.issue	12

Abstract:

PURPOSE: Inflammation is thought to play a key role in malignant disease and may play a significant part in the expression of cancer-related symptoms. Cannabidiol (CBD) is a bioactive compound in cannabis and is reported to have significant anti-inflammatory properties. METHOD: Serial C-reactive protein (CRP) levels were measured in all participants recruited to a randomised controlled trial of CBD versus placebo in patients with symptoms related to advanced cancer. A panel of inflammatory cytokines was measured over time in a subset of these patients. RESULTS: There was no difference between the two arms in the trajectory of CRP or cytokine levels from baseline to day 28. CONCLUSION: We were unable to demonstrate an anti-inflammatory effect of CBD in cancer patients. TRIAL REGISTRATION: ANZCTR 26180001220257, registered 20/07/2018.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/179759